Material Data Sheet
Quantity:200 μg 1 mg
Potent, reversible, cell-permeable inhibitor that specifically inhibits the 19S regulatory particle- associated deubiquitinases. b-AP15 has been shown to inhibit tumor progression in at least four solid tumor models, and also inhibits organ infiltration in an acute myeloid leukemia (AML) model. b-AP15 is made available through collaboration with Vivolux AB, Uppsala, Sweden.
Purity:> 98% by HPLC. Structure confirmed by 1H-NMR.
Solubility:Supplied as 10mM stock in DMSO (4.19 mg/ml). May hydrolyze slowly in aqueous buffers.
Inhibits purified 19S deubiquitinase activity using Ub-AMC as substrate (in vitro IC50=2.1μM).
Decreases HCT-116 cell viability at 72 hours (EC50=0.4μM).
Store at 2-8°C. Avoid multiple freeze/thaw cycles.
D' Arcy, P., et al. (2011) Nature Medicine. 17:1636-1640
Cain, C. SciBX 4(47); doi:10.1038/scibx.2011.1313